A Q2 Earnings Call: Mixed Revenue Performance, Margin Pressure, and Strategic Updates

Life sciences tools company Agilent Technologies (NYSE: A) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 6% year on year to $1.67 billion. Its non-GAAP EPS of $1.31 per share was 3.6% above analysts’ consensus estimates.

Is now the time to buy A? Find out in our full research report (it’s free).

StockStory’s Take

Agilent’s second quarter results reflected broad-based growth across most end markets and geographies, with particular strength in China, India, and environmental testing. CEO Padraig McDonnell attributed the 6% year-on-year revenue growth to stable demand for core instruments, continued recovery in the biopharma segment, and robust performance in pathology and PFAS (per- and polyfluoroalkyl substances) testing. Management also highlighted progress in its digital ecosystem, noting a 12% increase in digital orders, and pointed to operational changes—including the Ignite transformation initiative—that drove early wins in pricing and procurement. While most end markets performed as expected, academia and government remained soft, and management described the macroeconomic and geopolitical environment as “highly dynamic,” underscoring ongoing uncertainty.

Looking forward, Agilent’s guidance is shaped by ongoing tariff risks, a cautious approach to macroeconomic uncertainty, and confidence in its operational initiatives. Management maintained its full-year core growth and adjusted EPS outlook, citing the ability to offset incremental tariff costs through supply chain adjustments, pricing, and Ignite-driven efficiencies. CFO Bob McMahon noted, “A combination of supply chain moves, surcharges, and savings will allow us to fully mitigate tariff costs by next year.” The company expects continued momentum in PFAS testing, accelerating growth in its CDMO (contract development and manufacturing organization) segment, and further gains from newly launched products such as the Infinity III LC system and Seahorse XF Flex analyzer. However, management cautioned that near-term growth may be uneven given the dynamic external environment and timing of customer orders.

Key Insights from Management’s Remarks

Management pointed to diverse geographic and product performance, with China and environmental testing outpacing expectations, while transformative operational initiatives helped offset mounting tariff pressures.

• China and India outperformance: China delivered 10% growth, benefiting from stable demand and a favorable Lunar New Year comparison, while India posted high-teens growth. Management opened its first India solution center to support local demand for advanced testing and regulatory compliance.
• PFAS testing momentum: Agilent saw more than 70% year-over-year growth in PFAS testing, driven by global regulatory expansion and product innovation. The company cited its Infinity III and 6495D systems as increasingly critical for customers seeking sensitive, robust PFAS detection in water, food, and industrial materials.
• Biopharma and CDMO progress: The NASD (Nucleic Acid Solutions Division) and BIOVECTRA businesses reported high single-digit and high teens growth, respectively. Management highlighted improved visibility on future orders, with the BIOVECTRA acquisition expanding Agilent’s presence in GLP-1 and complex chemistries manufacturing.
• Operational transformation via Ignite: The Ignite initiative enabled enterprise-wide pricing, organizational streamlining, and procurement centralization, leading to over $130 million in expected profit contribution for the year. The company achieved full-year pricing realization targets within six months and projects $80 million in annualized savings from organizational changes.
• Tariff mitigation and supply chain agility: Agilent’s tariff task force responded quickly to shifts in US, China, and EU tariffs by moving production, centralizing procurement, and implementing targeted price surcharges. Management expects to fully offset tariff impacts in 2026, with minimal net impact for this year despite potential new EU tariff increases.

Drivers of Future Performance

Agilent’s outlook for the coming quarters hinges on successful tariff mitigation, continued product innovation, and steady demand in core end markets, balanced against macroeconomic uncertainty.

• Tariff mitigation and pricing actions: Management anticipates covering all incremental tariff costs in 2025 through a blend of supply chain adjustments, strategic pricing surcharges, and Ignite-driven procurement savings. The company expects these actions to fully neutralize tariff impacts by next year, though the evolving trade landscape remains a risk.
• Momentum in PFAS and CDMO segments: Agilent projects ongoing strength in PFAS testing, driven by expanding global regulations and the company’s technology leadership. The CDMO segment (NASD and BIOVECTRA) is expected to deliver double-digit growth in the second half, supported by a healthy order backlog and accelerating commercialization of new manufacturing programs.
• Replacement cycles and product launches: The adoption of new instruments, notably the Infinity III LC system, is fueling replacement cycles across pharma, environmental, and food testing labs. Management highlighted higher attach rates for services and consumables, and expects sales momentum to build as customers upgrade aging systems over the next several quarters.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will watch for (1) sustained momentum in PFAS testing and CDMO segment order growth, (2) evidence that Ignite-driven cost savings and pricing actions are offsetting tariff impacts and supporting margin stability, and (3) the pace of customer adoption for new instruments like the Infinity III LC system. Progress in these areas will be key to tracking Agilent’s ability to navigate external headwinds and deliver on its operational commitments.

Agilent currently trades at a forward P/E ratio of 19.1×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.